A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin, and US Sourced Avastin) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Samsung Bioepis
- 25 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 25 Sep 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.